Key Inclusion Criteria:

          1. Age 18 years or older.

          2. Histologically or pathologically confirmed diagnosis of locally recurrent or
             metastatic advanced malignancy.

          3. Disease progression after standard of care (SOC) therapy or in the opinion of the
             Investigator unlikely to benefit from SOC therapy.

          4. Measurable disease per RECIST version 1.1.

          5. Must have at least 1 tumor lesion that is accessible for IT injection of T3011 in the
             opinion of the investigator.

          6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

          7. Life expectancy > 12 weeks.

          8. Demonstrate adequate organ function as defined by acceptable laboratory testing
             results.

          9. Women of child-bearing potential (WCBP) and men must agree to use adequate
             contraception prior to study entry, while on study treatment, and for six months after
             receiving last dose of T3011. WCBP must have a negative serum pregnancy test prior to
             W1D1.

         10. Last dose of previous anticancer therapy ≥ 21 days, radiotherapy > 21 days, or
             surgical intervention > 21 days prior to the first dose of T3011.

         11. Recovered from all prior anticancer therapy toxicities.

         12. Willingness to provide fresh tumor biopsy specimens as specified in the Schedule of
             Assessments.

         13. Capable of understanding and complying with protocol requirements.

         14. Signed and dated institutional review board/independent ethics committee-approved
             informed consent form before any protocol-directed screening procedures are performed.

        Key Exclusion Criteria:

          1. Have only tumors with severe fibrosis and therefore not injectable.

          2. Patients with injectable tumors impinging upon major airways or blood vessels.

          3. Prior treatment with another oncolytic virus or cellular therapy.

          4. Requires continued concurrent therapy with any drug active against HSV.

          5. Systemic therapy with immunosuppressive agents within 28 days before the start of
             T3011 treatment.

          6. Live vaccines within 4 weeks of initiation of study treatment.

          7. Primary or acquired immunodeficient states.

          8. Pregnant or lactating.

          9. Prior organ transplantation.

         10. Active hepatitis B virus, hepatitis C virus, and HIV infection or a positive
             serological test at Screening within 14 days of dosing with T3011.

         11. Active autoimmune disease or medical conditions requiring chronic steroid.

         12. History of or current central nervous system metastases.

         13. History of seizure disorders within 6 months of Screening.

         14. Active oral or skin herpes lesion at Screening.

         15. Active interstitial lung disease (ILD)/pneumonitis or a history of ILD/pneumonitis
             requiring treatment with systemic steroids.

         16. Congestive heart failure, active coronary artery disease, unevaluated new onset angina
             within 3 months or unstable angina, or clinically significant cardiac arrhythmias.

         17. History of allergic reactions attributed to compounds of similar biological
             composition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody.

         18. Active infection with SARS-CoV-2 virus.

         19. Other systemic conditions or organ abnormalities that, in the opinion of the
             investigator, may interfere with the conduct and/or interpretation of the current
             study.